AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy.
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the...
Roche`s inavolisib combo cuts breast cancer progression by 57%
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be...
Astex Pharmaceuticals, a pharmaceutical company developing small molecule therapeutics for oncology and diseases of the central nervous system, has earned a milestone payment from AstraZeneca for the first commercial sale of Truqap plus Faslodex for HR-positive, HER2-negative locally advanced or metastatic breast cancer in the U.S. following the U.S. FDA’s approval.
TRUQAP™ (capivasertib) plus fulvestrant approved in the US
US FDA approves AstraZeneca`s breast cancer drug combination
The FDA and Eagle Pharmaceuticals have agreed on the next steps for the development of EA-114, an estrogen receptor antagonist and novel formulation of fulvestrant (Faslodex) used in the treatment of postmenopausal women with breast cancer. The consensus was reached in a Type C meeting with the regulatory agency and company representatives.
Eugia's Generic Fulvestrant Receives Approval in the U.S.
The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors, according to findings from the phase 3 SONIA trial (NCT03425838) presented at the 2023 ASCO Annual Meeting.